PL3638696T3 - Zastosowanie przeciwciała anty cd70 argx-110 w leczeniu ostrej białaczki szpikowej - Google Patents

Zastosowanie przeciwciała anty cd70 argx-110 w leczeniu ostrej białaczki szpikowej

Info

Publication number
PL3638696T3
PL3638696T3 PL18732064.3T PL18732064T PL3638696T3 PL 3638696 T3 PL3638696 T3 PL 3638696T3 PL 18732064 T PL18732064 T PL 18732064T PL 3638696 T3 PL3638696 T3 PL 3638696T3
Authority
PL
Poland
Prior art keywords
acute myeloid
myeloid leukaemia
treat acute
antibody argx
argx
Prior art date
Application number
PL18732064.3T
Other languages
English (en)
Inventor
Nicolas LEUPIN
Luc Van Rompaey
Hans De Haard
Adrian OCHSENBEIN
Carsten RIETHER
Original Assignee
argenx BV
University Of Bern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59462340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3638696(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by argenx BV, University Of Bern filed Critical argenx BV
Publication of PL3638696T3 publication Critical patent/PL3638696T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001138—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL18732064.3T 2017-06-16 2018-06-18 Zastosowanie przeciwciała anty cd70 argx-110 w leczeniu ostrej białaczki szpikowej PL3638696T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1709677.7A GB2567613A (en) 2017-06-16 2017-06-16 Treatment for acute myeloid leukaemia
PCT/EP2018/066144 WO2018229303A1 (en) 2017-06-16 2018-06-18 Use of anti cd70 antibody argx-110 to treat acute myeloid leukaemia

Publications (1)

Publication Number Publication Date
PL3638696T3 true PL3638696T3 (pl) 2024-07-22

Family

ID=59462340

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18732064.3T PL3638696T3 (pl) 2017-06-16 2018-06-18 Zastosowanie przeciwciała anty cd70 argx-110 w leczeniu ostrej białaczki szpikowej

Country Status (23)

Country Link
US (2) US20190106498A1 (pl)
EP (2) EP4389142A3 (pl)
JP (2) JP7498564B2 (pl)
KR (1) KR102799514B1 (pl)
CN (1) CN110730789A (pl)
AU (3) AU2018285731B2 (pl)
BR (1) BR112019026795A2 (pl)
CA (1) CA3063694A1 (pl)
DK (1) DK3638696T5 (pl)
EA (1) EA202090061A1 (pl)
ES (1) ES2974678T3 (pl)
FI (1) FI3638696T3 (pl)
GB (2) GB2567613A (pl)
HU (1) HUE066603T2 (pl)
IL (2) IL321494A (pl)
JO (1) JOP20190285A1 (pl)
LT (1) LT3638696T (pl)
MA (1) MA49377A (pl)
MX (1) MX2019015204A (pl)
PH (1) PH12019502477A1 (pl)
PL (1) PL3638696T3 (pl)
PT (1) PT3638696T (pl)
WO (1) WO2018229303A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2686347T3 (en) 2011-03-16 2018-06-25 Argenx Bvba Antibodies against CD70
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
GB2567613A (en) * 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
TWI848030B (zh) 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
EP3946322B1 (en) * 2019-03-29 2023-09-20 Novocure GmbH Methods for restoring sensitivity to ttfields in ttfields-resistant cancer cells with ptger3 inhibitors
JP7585231B2 (ja) * 2019-04-29 2024-11-18 イミュノジェン， インコーポレイテッド 抗ｃｄ１２３免疫複合体を含む治療的組み合わせ
WO2021055437A1 (en) * 2019-09-16 2021-03-25 The General Hospital Corporation Cd70 targeted chimeric antigen receptor (car) t cells and uses thereof
TWI877278B (zh) * 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
CN115803053A (zh) * 2020-06-30 2023-03-14 江苏恒瑞医药股份有限公司 抗cd70抗体及其应用
WO2022023379A1 (en) * 2020-07-28 2022-02-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for preventing and treating a cancer
JP2023539493A (ja) 2020-08-29 2023-09-14 アルジェニクス ビーブイ Ｂｃｌ－２阻害剤への低下した感度を有する患者の治療方法
CN114685657B (zh) * 2020-12-31 2024-08-16 康诺亚生物医药科技（成都）有限公司 一种功能增强型抗体阻断剂的开发及其应用
CN114720358B (zh) * 2022-04-11 2022-09-27 浙江普罗亭健康科技有限公司 一种质谱流式血液肿瘤免疫分型中替代侧向散射光信号的抗体组合及应用
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE472338T1 (de) 2003-02-20 2010-07-15 Seattle Genetics Inc Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
JP5222559B2 (ja) 2004-10-15 2013-06-26 シアトル ジェネティックス， インコーポレイテッド 癌および免疫障害の処置および予防のための抗ｃｄ７０抗体ならびにその使用
ES2477765T3 (es) 2005-04-19 2014-07-17 Seattle Genetics, Inc. Agentes de unión al anti-cd70 humanizado y usos de los mismos
JP2009509510A (ja) * 2005-09-26 2009-03-12 メダレックス インコーポレーティッド Ｃｄ７０に対するヒトモノクローナル抗体
CA2672468A1 (en) 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
DK2686347T3 (en) * 2011-03-16 2018-06-25 Argenx Bvba Antibodies against CD70
CN107325164A (zh) * 2011-05-31 2017-11-07 和黄生物膜医疗解决方案有限公司 细胞聚集体的分散和脱离
JP6343609B2 (ja) 2012-06-19 2018-06-13 アンブルックス, インコーポレイテッドAmbrx, Inc. 抗ｃｄ７０抗体薬物複合体
CN105073139B (zh) * 2013-02-14 2019-01-11 百时美施贵宝公司 妥布赖森化合物、制备和使用方法
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
GB2567613A (en) * 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia

Also Published As

Publication number Publication date
KR20200024823A (ko) 2020-03-09
GB201709677D0 (en) 2017-08-02
EP4389142A2 (en) 2024-06-26
DK3638696T5 (da) 2024-08-26
MA49377A (fr) 2020-04-22
AU2022200521A1 (en) 2022-02-17
US20190106498A1 (en) 2019-04-11
AU2025201328A2 (en) 2025-05-22
BR112019026795A2 (pt) 2020-06-30
US20250230252A1 (en) 2025-07-17
KR102799514B1 (ko) 2025-04-23
AU2018285731A1 (en) 2019-11-28
GB201712273D0 (en) 2017-09-13
AU2018285731B2 (en) 2021-11-04
IL321494A (en) 2025-08-01
ES2974678T3 (es) 2024-07-01
GB2567613A (en) 2019-04-24
JP7498564B2 (ja) 2024-06-12
PH12019502477A1 (en) 2020-07-20
AU2025201328A1 (en) 2025-03-20
CA3063694A1 (en) 2018-12-20
JOP20190285A1 (ar) 2019-12-15
MX2019015204A (es) 2020-08-17
CN110730789A (zh) 2020-01-24
HUE066603T2 (hu) 2024-08-28
IL271266A (en) 2020-01-30
EP3638696A1 (en) 2020-04-22
FI3638696T3 (fi) 2024-05-06
EP4389142A3 (en) 2024-08-21
EA202090061A1 (ru) 2020-04-13
JP2024109951A (ja) 2024-08-14
DK3638696T3 (da) 2024-05-06
LT3638696T (lt) 2024-06-25
EP3638696B8 (en) 2024-06-26
WO2018229303A1 (en) 2018-12-20
JP2020528044A (ja) 2020-09-17
NZ758854A (en) 2025-05-30
EP3638696B1 (en) 2024-03-06
PT3638696T (pt) 2024-05-03

Similar Documents

Publication Publication Date Title
PT3638696T (pt) Uso do anticorpo anti-cd70 argx-110 para tratar leucemia mielóide aguda
IL267803A (en) Methods for treating cancer with anti-tim-3 antibodies
IL264674B1 (en) Antibodies to siglec7 for cancer treatment
HUE071008T2 (hu) Pridopidin alkalmazása mûködési hanyatlás kezelésére
IL253462B2 (en) Cancer treatment with monoclonal antibodies against a latency-related peptide
EA201791208A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
HUE065242T2 (hu) LAG-3-pozitív tumorok kezelése
MA41449A (fr) Polythérapies pour le traitement de cancers
HUE061471T2 (hu) Imetelstat és venetoclax kombinációk akut mieloid leukémia kezelésére
EP3400010A4 (en) ANTI-HER2 COMBINATIONS FOR THE TREATMENT OF TUMORS
IL307850A (en) A combination of a histone deacetylase inhibitor and an antibody against programmed cell death protein 1 for the treatment of cancer
EP3645040A4 (en) USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF CANCERS
IL259416A (en) Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of ovarian cancer
IL268460A (en) Treatment of bladder cancer with an antibody against pd-l1
EP3442564A4 (en) COMPOSITION OF PROTEZYMS FOR CANCER TREATMENT
IL268187A (en) Use of Snickepok to treat stroke
SG11202000839TA (en) Methods of treating cancer by inhibiting setd2
IL271430A (en) Methods for treating opioid use disorders
PL3582764T3 (pl) Leczenie zaburzeń związanych ze spożywaniem alkoholu
EP3538102A4 (en) INHIBITATION OF KMT2D FOR TREATING CANCER
GB2580157B (en) Treatment of produced hydrocarbons
GB2580145B (en) Treatment of produced hydrocarbons
HK40030315A (zh) 抗-fam19a5抗体用於治疗癌症的用途
IT201700108039A1 (it) Composizione per il trattamento della costipazione
IT201700108033A1 (it) Composizione per il trattamento della costipazione